WaveMan
WaveMan · Company
ENTX · Entera Bio Ltd.
> Search tickers & screens ⌘K
LIVE
← All companies

ENTX Entera Bio (ENTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001638097
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
15
13F, latest reported quarter

What the filings say about ENTX

Activist stakes (13D), 180 days
1 filing
Largest: 10.0% of the class

Entera Bio insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Entera Bio Ltd. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Germano Geno J
Director
BUY
2026-03-11 SECtraded 2026-03-09
20,000
$26.0K
+116.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Feb 10, 2026.
  • The trade is 50.0% of the 40,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Germano Geno J bought about $26.0K of ENTX on Mar 9, 2026; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.
Ellis Sean
Director
BUY
2026-03-09 SECtraded 2026-03-05
10,000
$12.3K
+91.9%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Feb 9, 2026.
  • -2.5% median (+6.2% mean) 90-day return after 5 previous buys.
  • The trade is 5.3% of the 188,098 shares held after it.
  • 3 other insiders bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ellis Sean bought about $12.3K of ENTX on Mar 5, 2026; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.
Rubin Steven D
Director
BUY
2026-02-17 SECtraded 2026-02-12
5,000
$7.5K
+104.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Feb 9, 2026.
  • The trade is 33.3% of the 15,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Rubin Steven D bought about $7.5K of ENTX on Feb 12, 2026; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.
Taitel Haya
Director
BUY
2026-02-11 SECtraded 2026-02-10
7,500
$11.1K
+88.2%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jan 12, 2024.
  • +144.0% median (+110.9% mean) 90-day return after 3 previous buys.
  • 3 other insiders bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Taitel Haya bought about $11.1K of ENTX on Feb 10, 2026; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.
Germano Geno J
Director
BUY
2026-02-11 SECtraded 2026-02-10
20,000
$29.8K
+88.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • 3 other insiders bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Germano Geno J bought about $29.8K of ENTX on Feb 10, 2026, the largest insider purchase at the company since 2023; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.
36 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 31 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
15 funds bought in last quarter
below 73% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.4% of the float short (float per yahoo 2026-10-27) · 7.2 days to cover · settled 2026-10-15
below 58% of Pharma & Biotech
The situation: each line is one rule over one dataset
BIOTECHNOLOGY VALUE FUND L P disclosed a 5%+ stake (5.3%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ENTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+33.6%12M
-53%-8%+38%+83%2025-102025-122026-022026-042026-062026-082026-10 2026-02-10 · Germano Geno J bought $29.8K2026-03-09 · Germano Geno J bought $26.0K2026-02-09 · Ellis Sean bought $22.3K2025-12-29 · Toledano Miranda Jayne bought $19.9K2026-03-05 · Ellis Sean bought $12.3K2026-02-09 · Rubin Steven D bought $12.0K2026-02-10 · Taitel Haya bought $11.1K2026-02-12 · Rubin Steven D bought $7.5K2026-08-04 · BIOTECHNOLOGY VALUE FUND L P filed a 5%+ stake (5.3%)2026-08-04 · BVF I GP LLC filed a 5%+ stake (5.3%)2026-08-04 · BIOTECHNOLOGY VALUE FUND II LP filed a 5%+ stake (3.9%)2026-08-04 · BVF II GP LLC filed a 5%+ stake (3.9%)2026-08-04 · Biotechnology Value Trading Fund OS LP filed a 5%+ stake (0.7%)2026-08-04 · BVF Partners OS Ltd. filed a 5%+ stake (0.7%)2026-08-04 · BVF GP HOLDINGS LLC filed a 5%+ stake (9.2%)2026-08-04 · BVF PARTNERS L P/IL filed a 5%+ stake (9.99%)2026-08-04 · BVF INC/IL filed a 5%+ stake (9.99%)2026-08-04 · LAMPERT MARK N filed a 5%+ stake (9.99%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ENTX: institutional holders (13F)

13F holdings, latest reported quarter
Knoll Capital Management, LLC
5,881,879 sh
$10.4M
BVF INC/IL
2,425,000 sh
$4.3M
Siren, L.L.C.
736,457 sh
$1.3M
RENAISSANCE TECHNOLOGIES LLC
368,847 sh
$652.9K
Parkman Healthcare Partners LLC
274,497 sh
$485.9K

Congress trades in ENTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
BIOTECHNOLOGY VALUE FUND L P
Activist 13D · 2026-08-04
5.3%
BVF I GP LLC
Activist 13D · 2026-08-04
5.3%
BIOTECHNOLOGY VALUE FUND II LP
Activist 13D · 2026-08-04
3.9%
BVF II GP LLC
Activist 13D · 2026-08-04
3.9%
Biotechnology Value Trading Fund OS LP
Activist 13D · 2026-08-04
0.7%

ENTX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
1 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Miranda Toledano
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.5M
$1.4M
$518.0K
+123%
n/a
2024
$1.1M
$2.2M
$485.0K
+112%
n/a
2023
$950.0K
$483.0K
$385.0K
-79%
n/a
2022
$679.0K
$761.0K
$502.0K
-74%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 15 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ENTX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
0.04x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$484.2M
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-12
Net income-$11.4M-$9.5M
Cash$7.1Mn/a
Long-term debt$393.0K$0
SEC XBRL, fiscal years, as known on 2026-10-28

ENTX Stock Sonar score 3/7 axes

Find similar shapesCompare

ENTX ranks highest on risk and compliance (71st percentile) and financial health (65th), and lowest on institutional and government (27th), among Pharma & Biotech peers.

Financial health
65
Inputs
  • Debt to equity0.04x · 65 pct, sector of 352
  • Cash flow to debtneeds four quarters of operating cash flow
Institutional and government
27
Inputs
  • Funds adding, latest quarter15 · 27 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
71
Inputs
  • Short interest, % of float+4.4% · 61 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.2% · 81 pct, sector of 511
4 not measured: Profitability, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ENTX filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 10.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies